Details
Stereochemistry | EPIMERIC |
Molecular Formula | C24H23N3O6S.C10H8O3S |
Molecular Weight | 689.755 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)C1=CC=C2C=CC=CC2=C1.[H][C@]34SC(C)(C)[C@@H](N3C(=O)[C@H]4NC(=O)[C@H](N)C5=CC=CC=C5)C(=O)OC6OC(=O)C7=C6C=CC=C7
InChI
InChIKey=ROOMFXLKCBAVMC-WVFSJLEKSA-N
InChI=1S/C24H23N3O6S.C10H8O3S/c1-24(2)17(22(31)33-23-14-11-7-6-10-13(14)21(30)32-23)27-19(29)16(20(27)34-24)26-18(28)15(25)12-8-4-3-5-9-12;11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h3-11,15-17,20,23H,25H2,1-2H3,(H,26,28);1-7H,(H,11,12,13)/t15-,16-,17+,20-,23?;/m1./s1
Molecular Formula | C24H23N3O6S |
Molecular Weight | 481.521 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C10H8O3S |
Molecular Weight | 208.234 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/776328
Sources: http://www.ncbi.nlm.nih.gov/pubmed/776328
The phthalidyl thiazolidine carboxylic ester of ampicillin, talampicillin (Talpen, Beecham), has been introduced recently to improve absorption and to reduce these side effects. After oral administration talampicillin is rapidly absorbed and hydrolysed by tissue esterases in the intestinal wall to release into the circulation ampicillin and the ester moiety, mainly 2-hydroxymethyl-benzoic acid. No unchanged talampicillin is detectable in the peripheral blood. It is not approved by the FDA for use in the United States
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: http://www.ncbi.nlm.nih.gov/pubmed/776328 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Talpen Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/776328
for seven days at a dosage of 390 mg three times daily or 750 mg twice daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:06:24 GMT 2023
by
admin
on
Sat Dec 16 10:06:24 GMT 2023
|
Record UNII |
JB791E7242
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71953-01-0
Created by
admin on Sat Dec 16 10:06:24 GMT 2023 , Edited by admin on Sat Dec 16 10:06:24 GMT 2023
|
PRIMARY | |||
|
JB791E7242
Created by
admin on Sat Dec 16 10:06:24 GMT 2023 , Edited by admin on Sat Dec 16 10:06:24 GMT 2023
|
PRIMARY | |||
|
9831447
Created by
admin on Sat Dec 16 10:06:24 GMT 2023 , Edited by admin on Sat Dec 16 10:06:24 GMT 2023
|
PRIMARY | |||
|
235836
Created by
admin on Sat Dec 16 10:06:24 GMT 2023 , Edited by admin on Sat Dec 16 10:06:24 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |